Alnylam Pharmaceuticals
ALNY
#638
Rank
C$45.07 B
Marketcap
$347.39
Share price
-0.59%
Change (1 day)
39.23%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -C$0.25 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are C$2.09 Billion. In 2023 the company made an earning of -C$0.45 Billion, an increase over its 2022 earnings that were of -C$1.39 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -C$0.25 Billion-43.88%
2023 -C$0.45 Billion-67.84%
2022 -C$1.39 Billion36.93%
2021 -C$1.01 Billion-8.04%
2020 -C$1.1 Billion-15.66%
2019 -C$1.31 Billion12.23%
2018 -C$1.16 Billion62.91%
2017 -C$0.72 Billion17.78%
2016 -C$0.61 Billion43.44%
2015 -C$0.43 Billion60.69%
2014 -C$0.27 Billion98.2%
2013 -C$0.14 Billion
2011 -C$78.05 Million27.48%
2010 -C$61.23 Million-10.92%
2009 -C$68.73 Million95.77%
2008 -C$35.11 Million
2006 -C$56.25 Million-9.13%
2005 -C$61.9 Million34.74%
2004 -C$45.94 Million36.79%
2003 -C$33.59 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$0.83 Billion 210.42%๐Ÿ‡บ๐Ÿ‡ธ USA
C$7.07 B-2,759.15%๐Ÿ‡บ๐Ÿ‡ธ USA
C$0.18 B-169.24%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$0.17 Billion-36.94%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$58.91 Million-77.86%๐Ÿ‡บ๐Ÿ‡ธ USA
C$18.12 B-6,912.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
C$10.54 B-4,063.98%๐Ÿ‡ซ๐Ÿ‡ท France
C$0.59 B-324.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel